Blood pressure control remains one of the most powerful tools for reducing cardiovascular and kidney complications in people with diabetes. While clinicians have traditionally focused on achieving targets below 140/90 mmHg, recent evidence and the 2026 American Diabetes Association Standards of Care support a more intensive approach for selected high-risk …

For many people living with diabetes, gaining access to an automated insulin delivery (AID) system can be life-changing. These technologies help improve glycemic outcomes, reduce hypoglycemia risk, and ease the daily burden of diabetes management. Yet despite their proven benefits, many patients continue to face lengthy delays before gaining access. …

For years, hospital admission often meant disconnecting patients from their personal diabetes devices. Continuous glucose monitors (CGMs) and insulin pumps were frequently removed, even when patients had used them successfully at home. However, the 2026 American Diabetes Association (ADA) Standards of Care introduce a significant shift in how hospitals approach …

The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …

As cancer treatment becomes increasingly sophisticated, clinicians are encountering a growing metabolic challenge. Cancer therapy–induced hyperglycemia has emerged as an important concern with the expanding use of immunotherapies and targeted therapies. In some patients, hyperglycemia develops gradually. In others, particularly those receiving immune checkpoint inhibitors, severe diabetes and diabetic ketoacidosis …

Continuous glucose monitoring (CGM) has transformed diabetes management by giving patients real-time glucose data, trend arrows, and alerts that support better daily decisions. Yet some patients stop using their CGM within days of starting. Often, the problem is not the device itself. Instead, early frustration begins when patients leave the …

For many people living with diabetes, insulin is more than a medication—it is a lifeline. Yet despite its critical role, some patients stop taking insulin without informing their healthcare provider. The reasons vary widely and may include medication costs, treatment fatigue, fear of side effects, weight gain concerns, or misunderstandings …

Sexual health remains one of the most overlooked aspects of diabetes management, despite its significant impact on quality of life. While clinicians routinely discuss glycemic control, cardiovascular risk, and medication adherence, conversations about sexual function are often avoided by both patients and healthcare providers. Yet sexual health concerns related to …

Many healthcare providers focus heavily on daytime glucose control, yet some of the most dangerous hypoglycemic episodes occur while patients are asleep. Despite major advances in insulin therapy and glucose monitoring, nocturnal hypoglycemia remains a significant clinical concern for people living with diabetes. Because symptoms often go unnoticed during sleep, …

When a healthcare provider writes a prescription for diabetes medication, most assume the treatment journey has begun. However, for many patients, the process never moves beyond the prescription pad. This hidden problem, often discussed as primary nonadherence in diabetes care, occurs when patients fail to obtain a newly prescribed medication. …